Investor Strategy

Europe’s drugs regulator speeds up the approval process for Pfizer and BioNTech’s COVID-19 vaccine

  • Europe’s drugs regulator has fast-tracked the approval process for a COVID-19 vaccine developed by Germany’s BioNTech and the US pharmaceutical group Pfizer.
  • The “rolling review” by the European Medicines Agency could speed up authorization of the vaccine.
  • It means the EMA does not have to wait for trials to finish before reviewing data.
  • The decision to begin the review is based on the results of earlier clinical trials that found the vaccine triggered an immune response in humans, the EMA said on Tuesday.
  • Visit Business Insider’s homepage for more stories.

Europe’s drug regulator has taken action that could speed up the approval of a COVID-19 vaccine developed by Germany’s BioNTech and the US pharmaceutical group Pfizer.

A new “rolling review” launched by the European Medicines Agency on Tuesday will evaluate how effective the vaccine is in real time as data returns from patient trials. This means the agency will not wait for BioNTech and Pfizer to finish their trials and submit all the data at once.

The review could therefore speed up authorization of the vaccine should it ultimately prove safe and effective.

The agency on Tuesday said it had begun looking at data from laboratory studies on the vaccine. It would continue to assess data until it had enough to make a final decision, it said.

The decision to kick off the rolling review of BioNTech and Pfizer’s COVID-19 vaccine is based on the results of earlier clinical trials in adults that found the vaccine triggered an immune response, the agency said.

The vaccine is the second COVID-19 candidate to be approved for a rolling review by the EMA. The agency confirmed on Thursday that it had started a rolling review of the vaccine developed by AstraZeneca and the University of Oxford. This followed a pause in trials of the vaccine, after a participant reported severe neurological symptoms — the UK has resumed trials, while the US is still investigating.

Pfizer’s vaccine is in late-stage studies in the US, Brazil, South Africa, and Argentina.

BioNTech and Pfizer’s vaccine could be one of the earliest COVID-19 candidates to be approved in Europe. The race for a vaccine on the continent is becoming ever more urgent as the infection rate rises.

The known global coronavirus death toll passed 1 million on September 29.

LoadingSomething is loading.

Do you have a personal experience with the coronavirus you’d like to share? Or a tip on how your town or community is handling the pandemic? Please email covidtips@businessinsider.com and tell us your story.

Get the latest coronavirus business & economic impact analysis from Business Insider Intelligence on how COVID-19 is affecting industries.

Digital Health Briefing


Healthcare Explained:

Telehealth Industry
Value-Based Care
Senior Care & Assisted Living Market
Medical Devices & Wearable Tech
AI in Healthcare
Remote Patient Monitoring

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Your daily news source covering investing ideas, market stocks, business, retirement tips from Wall St. to Silicon Valley.

Disclaimer:

TheProficientInvestor.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 TheProficientInvestor. All Rights Reserved.

To Top

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!